Home › Funds › Affinity Asset Advisors, LLC › TRAX
Affinity Asset Advisors, LLC position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
Affinity Asset Advisors, LLC reported holding 2,080,000 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$73.7M, representing 3.43% of its reported portfolio and ranking #6 among its reported holdings. Affinity Asset Advisors, LLC has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's TRAX position evolved
Affinity Asset Advisors, LLC first disclosed a stake in TRAX in Q2 2026 at 2,032,012 shares (US$40.9M). The position peaked in Q3 2026 at 2,080,000 shares, worth US$73.7M. Across 2 filings, Affinity Asset Advisors, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,080,000 shares valued at US$73.7M — an increase of 47,988 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.03M | $40.88M | New |
| Q3 2026 | 2.08M | $73.72M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 176 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$63.9M), TCG Crossover Management, LLC (US$58.3M), Trails Edge Capital Partners, LP (US$30.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- EcoR1 Capital, LLC 3.17M sh · $63.87M · Q2 2026
- TCG Crossover Management, LLC 2.90M sh · $58.25M · Q2 2026
- Trails Edge Capital Partners, LP 1.51M sh · $30.46M · Q2 2026
- Sanofi 821.92K sh · $29.13M · Q3 2026
- Vestal Point Capital, LP 1.01M sh · $20.38M · Q2 2026
- 683 Capital Management, LLC 750.00K sh · $15.09M · Q2 2026
- STEMPOINT CAPITAL LP 622.72K sh · $12.53M · Q2 2026
- Palo Alto Investors LP 603.49K sh · $12.14M · Q2 2026
- Sofinnova Investments, Inc. 565.20K sh · $11.37M · Q2 2026
- Ally Bridge Group (NY) LLC 284.29K sh · $5.72M · Q2 2026
- Opaleye Management Inc. 65.00K sh · $1.31M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held TRAX?
Affinity Asset Advisors, LLC has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Affinity Asset Advisors, LLC's current position in TRAX?
As of Q3 2026, Affinity Asset Advisors, LLC holds 2.08M shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $73.72M, representing 3.43% of its reported portfolio and ranking #6.
Has Affinity Asset Advisors, LLC been buying or selling TRAX?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in TRAX. The position peaked in Q3 2026 at 2.08M shares.
Which other funds hold TRAX?
Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Trails Edge Capital Partners, LP, among 176 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.